Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Zevra Therapeutics, Inc. (ZVRA)
Company Research
Source: Yahoo! Finance
commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company has granted as of March 18, 2026 an equity inducement award to Justin Renz, the Company's new Chief Financial Officer pursuant to the Company's 2023 Employment Inducement Award Plan (as amended and/or restated, the “Inducement Award Plan”). The equity award was approved by the Compensation Committee of the Board of Directors in accordance with Nasdaq Rule 5635(c)(4) and made as a material inducement to Mr. Renz upon acceptance of employment with Zevra. The Company granted Mr. Renz a new hire option to purchase 300,000 shares of Zevra's common stock. The option has a 10-year term and an exercise price per share equal to $9.55, which was the closing price of Zevra's common stock on March 18, 2026. The option vests over four years, subject to Mr. Renz's continued service through the applicable vesting dates. About Zevra Therapeutics, Inc. Zevra Therapeutics,
Show less
Read more
Impact Snapshot
Event Time:
ZVRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZVRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZVRA alerts
High impacting Zevra Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ZVRA
News
- Zevra Ties NPC Testing Push To Valuation Gap And New CFO [Yahoo! Finance]Yahoo! Finance
- Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements [Yahoo! Finance]Yahoo! Finance
- Zevra Therapeutics (ZVRA) is now covered by BTIG Research. They set a "buy" rating and a $23.00 price target on the stock.MarketBeat
- Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million [Yahoo! Finance]Yahoo! Finance
ZVRA
Earnings
- 3/9/26 - Beat
ZVRA
Sec Filings
- 3/19/26 - Form 4
- 3/19/26 - Form 3
- 3/16/26 - Form 144
- ZVRA's page on the SEC website